Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Prevention Research

Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation

Sanjeev Shukla and Sanjay Gupta
Sanjeev Shukla
Case Western Reserve Univ., Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Gupta
Case Western Reserve Univ., Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2007
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

Abstract

1576

Cancer prevention is profoundly dependent on the p53 tumor suppression protein as it functions in regulating growth and protecting cells from malignant transformation. The ability of p53 in providing prevention against cancer lies in the elimination of damaged or infected cells by causing cell cycle arrest and/or apoptosis. Several studies have demonstrated the anti-tumor activity of p53 and in fact, p53 is the most frequently altered protein in human cancer. Approximately, 50% of all human malignancies harbor mutations or deletions in the TP53 gene that disable the tumor suppressor function of the encoded protein. The other half of human tumors expresses wild type protein and encodes further defects in the p53 signaling pathway playing critical role in tumorigenesis. Agents which can differentially activate wild-type p53 in cancer cells could be develop for chemoprevention. Apigenin (4’,5,7-trihydroxyflavone) is one such agent that potentially activates wild-type p53 and induces apoptosis in cancer cells. We conducted detailed studies to understand its mechanism of action. Exposure of human prostate cancer 22Rv1 cells, harboring wild type p53, to growth suppressive concentration (10-80 μM) of apigenin resulted in i) stabilization of p53 by phosphorylation on critical serine sites, ii) p14/ARF-mediated downregulation of murine double minute (MDM) 2 protein, and iii) induction of WAF1/p21 in dose- and time- dependent manner. Apigenin, at these doses resulted in reactive oxygen species (ROS) generation which was accompanied by disruption of mitochondrial membrane potential, cytosolic release of cytochrome C and apoptosis. Interestingly, we observed accumulation of p53 to the mitochondria which was rapid and occurred between 1-3 h after apigenin treatment. All these effects were significantly blocked by pretreatment with antioxidant, N-acetylcystiene, and a well known p53 inhibitor, pifithrin. Apigenin-mediated p53 activation and apoptosis was further attenuated by p53 anti-sense treatment. Exposure of cells to apigenin further led to decrease in Bcl-2 expression and increase in Bax thereby shifting the Bax/Bcl-2 in favor of apoptosis. This altered expression of Bcl-2 family members triggered activation of the initiator caspases 9 and 8 followed by activation of effector caspase 3. Treatment of 22Rv1 cells with general caspase inhibitor, Z-VAD-FMK and a specific caspase-3 inhibitor, DEVD-CHO partially rescued these cells from apigenin-induced apoptosis. Taken together, the present study indicates that apigenin-induced apoptosis in 22Rv1 cells is mediated by ROS-dependent disruption of the mitochondrial membrane potential and stabilization of p53.

Footnotes

  • 98th AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 67 (9 Supplement)
May 2007
Volume 67, Issue 9 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
Sanjeev Shukla and Sanjay Gupta
Cancer Res May 1 2007 (67) (9 Supplement) 1576;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation
Sanjeev Shukla and Sanjay Gupta
Cancer Res May 1 2007 (67) (9 Supplement) 1576;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Prevention Research

  • Abstract 512: Gene expression profiling reveals tumor immunobiological differences in prostate cancer between African-American and European-American men
  • Abstract LB-242: Aberrant crypt foci (ACF) are not surrogate biomarkers of sporadic adenoma prevention with celecoxib: Results from the Adenoma Prevention with Celecoxib (APC) trial
  • Abstract LB-333: Antagonistic interaction effects of aspirin and folic acid on inflammatory markers
Show more Prevention Research

Preclinical Prevention Studies 1: Novel Agents: Oral Presentations - Proffered Abstracts

  • Substitution of sulfur by selenium in S,S’-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea (PBIT), an established iNOS inhibitor, significantly enhances the induction of apoptosis and p53 protein expression in human non-small cell lung cancer.
  • Effects of EGCG on activation of the IGF/IGF-1R system in human hepatoma cells
  • D,L-Sulforaphane-mediated induction of p21 inhibits G2-M transition in LNCaP human prostate cancer cells
Show more Preclinical Prevention Studies 1: Novel Agents: Oral Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement